<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02332577</url>
  </required_header>
  <id_info>
    <org_study_id>PRISTL06562</org_study_id>
    <secondary_id>U1111-1160-6001</secondary_id>
    <nct_id>NCT02332577</nct_id>
  </id_info>
  <brief_title>Study to Compare the Efficacy of Pristinamycin (Pyostacine ®) Versus Amoxicillin in the Treatment of Acute Community Acquired Pneumonia</brief_title>
  <official_title>A Multi-centre, Non-inferiority, Randomized, Double-blind, Phase IV Study Comparing Pristinamycin (2g x 2 Per Day for 2 Days Then 1g x 3 Per Day for 5 to 7 Days) to Amoxicillin (1g x 3 Per Day) for 7 to 9 Days in Adults With Acute Community Acquired Pneumonia With a PORT Score of II or III</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Sanofi</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Sanofi</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Primary Objective:&#xD;
&#xD;
      To evaluate the clinical efficacy of pristinamycin at a dose of 2g x 2/day for 2 days then 1g&#xD;
      x 3/day for 5 to 7 days versus amoxicillin 1g x3 /day for 7 to 9 days, 5 to 9 days after the&#xD;
      end of treatment.&#xD;
&#xD;
      Secondary Objectives:&#xD;
&#xD;
      To evaluate the clinical efficacy in a subpopulation bacteriologically documented at&#xD;
      inclusion and according to procalcitonin level.&#xD;
&#xD;
      To evaluate the efficacy of treatments against pneumococcus. To evaluate the rate of relapse&#xD;
      and mortality 30±2 days after treatment is started.&#xD;
&#xD;
      To document failures. To collect and follow up adverse events.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The total study duration for each patient is 1 month with a treatment period of 7 to 9 days&#xD;
      and a follow-up period of 21 to 23 days.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 30, 2015</start_date>
  <completion_date type="Anticipated">May 30, 2025</completion_date>
  <primary_completion_date type="Anticipated">May 30, 2025</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percentage of patients cured established from the clinical course and pulmonary radiological course</measure>
    <time_frame>5 to 9 days post-treatment</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of cured patients evaluated by bacteriological documentation and procalcitonin levels</measure>
    <time_frame>5 to 9 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of cured patients evaluated by bacteriological documentation for pneumococcus</measure>
    <time_frame>5 to 9 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients with relapse</measure>
    <time_frame>at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mortality rate</measure>
    <time_frame>at Day 30</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of documented failures</measure>
    <time_frame>5 to 9 days post-treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients with adverse events</measure>
    <time_frame>up to Day 30</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">500</enrollment>
  <condition>Pneumonia</condition>
  <arm_group>
    <arm_group_label>Pristinamycin + Placebo</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Pristinamycin: 500 mg tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days Amoxicillin Placebo: capsule, 2 capsules x 3 /day for 7 to 9 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Amoxicillin + Placebo</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Amoxicillin: 500 mg capsule, 2 capsules x 3/day for 7 to 9 days Pristinamycin Placebo: tablet, 4 tablets x 2/day for 2 days then 2 tablets x 3/day for 5 to 7 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRISTINAMYCIN XRP7263</intervention_name>
    <description>Pharmaceutical form:tablet 500 mg Route of administration: oral</description>
    <arm_group_label>Pristinamycin + Placebo</arm_group_label>
    <other_name>Pyostacine ®</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin</intervention_name>
    <description>Pharmaceutical form:capsule 500 mg Route of administration: oral</description>
    <arm_group_label>Amoxicillin + Placebo</arm_group_label>
    <other_name>Amoxicilline EG</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Amoxicillin Placebo</intervention_name>
    <description>Pharmaceutical form: capsule Route of administration: oral</description>
    <arm_group_label>Pristinamycin + Placebo</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PRISTINAMYCIN Placebo</intervention_name>
    <description>Pharmaceutical form:Tablet Route of administration: Oral</description>
    <arm_group_label>Amoxicillin + Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion criteria:&#xD;
&#xD;
        Male or female more than 18 years old with a presumed bacterial acute community acquired&#xD;
        pneumonia presenting a PORT score of II or III (Fine II or III).&#xD;
&#xD;
        The acute community acquired pneumonia is defined by:&#xD;
&#xD;
          -  Pulmonary x-ray (carried out within the 48 hours prior to randomization) showing new&#xD;
             lobar or multilobar infiltrates.&#xD;
&#xD;
          -  At least 4 functional and/or clinical symptoms from among the following:&#xD;
&#xD;
          -  Fever characterized by a temperature of more than 38.5 at least once within 24h prior&#xD;
             to inclusion.&#xD;
&#xD;
          -  Appearance or aggravation of a cough.&#xD;
&#xD;
          -  Appearance of purulent expectoration.&#xD;
&#xD;
          -  Appearance or aggravation of dyspnoea.&#xD;
&#xD;
          -  Tachypnoea&#xD;
&#xD;
          -  Chest pain&#xD;
&#xD;
          -  A characteristic sign on percussion and/or auscultation associated with a pulmonary&#xD;
             condensation focus.&#xD;
&#xD;
        Exclusion criteria:&#xD;
&#xD;
        Patients having been diagnosed with legionellosis.&#xD;
&#xD;
        Patients having received systemic antibiotic therapy of over 24 hours within the week&#xD;
        preceding the start of study treatment.&#xD;
&#xD;
        Associated neoplasm (active cancer [of whatever type, solid or haematological] or diagnosed&#xD;
        within the year other than basocellular skin cancer).&#xD;
&#xD;
        Severe or very severe chronic obstructive pulmonary disease (COPD) (GOLD3 and GOLD4).&#xD;
&#xD;
        History of bacterial pneumonia in the past 12 months.&#xD;
&#xD;
        Bronchopulmonary diseases likely to interfere with the assessment of the therapeutic&#xD;
        response.&#xD;
&#xD;
        Known hypersensitivity to streptogramins, penicillin and other betalactamines or excipients&#xD;
        of the treatments studied.&#xD;
&#xD;
        History of severe skin reaction after taking pristinamycin or amoxicillin.&#xD;
&#xD;
        Kidney disease (chronic kidney failure or creatinine clearance ≤30 mL/minute).&#xD;
&#xD;
        Patients treated with allopurinol, colchicine, immunosuppressants (cyclosporin, tacrolimus,&#xD;
        mycophenolate mofetil, methotrexate, biotherapies) oral anticoagulants in the previous 6&#xD;
        months or during the study.&#xD;
&#xD;
        Known HIV infection, whatever the stage.&#xD;
&#xD;
        The above information is not intended to contain all considerations relevant to a patient's&#xD;
        potential participation in a clinical trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Clinical Sciences &amp; Operations</last_name>
    <role>Study Director</role>
    <affiliation>Sanofi</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Trial Transparency email recommended (Toll free number for US &amp; Canada)</last_name>
    <phone>800-633-1610</phone>
    <phone_ext>1 then #</phone_ext>
    <email>Contact-Us@sanofi.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Investigational Site Number :250029</name>
      <address>
        <city>Avoine</city>
        <zip>37420</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250015</name>
      <address>
        <city>COLOMBES Cedex</city>
        <zip>92701</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250010</name>
      <address>
        <city>Grenoble</city>
        <zip>38043</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250032</name>
      <address>
        <city>La Riche</city>
        <zip>37520</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250023</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250022</name>
      <address>
        <city>Paris</city>
        <zip>75010</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250004</name>
      <address>
        <city>PRINGY Cedex</city>
        <zip>74374</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250001</name>
      <address>
        <city>Saint Priest en Jarez</city>
        <zip>42277</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250031</name>
      <address>
        <city>Segre</city>
        <zip>49500</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Completed</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :250034</name>
      <address>
        <city>Tours</city>
        <zip>37000</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788001</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788002</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788004</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788005</name>
      <address>
        <city>Ariana</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788014</name>
      <address>
        <city>La marsa</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788007</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788011</name>
      <address>
        <city>Monastir</city>
        <zip>5000</zip>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Investigational Site Number :788009</name>
      <address>
        <city>Sfax</city>
        <country>Tunisia</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location_countries>
    <country>France</country>
    <country>Tunisia</country>
  </location_countries>
  <removed_countries>
    <country>Morocco</country>
  </removed_countries>
  <verification_date>October 19, 2021</verification_date>
  <study_first_submitted>January 5, 2015</study_first_submitted>
  <study_first_submitted_qc>January 5, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 7, 2015</study_first_posted>
  <last_update_submitted>October 19, 2021</last_update_submitted>
  <last_update_submitted_qc>October 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pneumonia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Amoxicillin</mesh_term>
    <mesh_term>Pristinamycin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

